BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Risitano AM, Röth A, Soret J, Frieri C, de Fontbrune FS, Marano L, Alashkar F, Benajiba L, Marotta S, Rozenberg I, Milojevic J, End P, Nidamarthy PK, Junge G, Peffault de Latour R. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021;8:e344-54. [PMID: 33765419 DOI: 10.1016/S2352-3026(21)00028-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Banerjee P, Veuskens B, de Jorge EG, Józsi M, Baeumner AJ, Steiner MS, Pouw RB, Toonen EJM, Pauly D, Poppelaars F; SciFiMed Consortium. Evaluating the clinical utility of measuring levels of factor H and the related proteins. Mol Immunol 2022;151:166-82. [PMID: 36162225 DOI: 10.1016/j.molimm.2022.08.010] [Reference Citation Analysis]
2 Risitano AM, Frieri C, Urciuoli E, Marano L. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. Immunological Reviews. [DOI: 10.1111/imr.13137] [Reference Citation Analysis]
3 Girmenia C, Barcellini W, Bianchi P, Di Bona E, Iori AP, Notaro R, Sica S, Zanella A, De Vivo A, Barosi G, Risitano A; scientific committee of the Associazione Italiana Emoglobinuria Parossistica Notturna (AIEPN). Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Rev 2022;:101013. [PMID: 36117056 DOI: 10.1016/j.blre.2022.101013] [Reference Citation Analysis]
4 Lee JW, Brodsky RA, Nishimura JI, Kulasekararaj AG. The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments. Expert Rev Clin Pharmacol 2022;:1-11. [PMID: 35980222 DOI: 10.1080/17512433.2022.2109462] [Reference Citation Analysis]
5 Han B, Ji J, Zhang B, Bai H, Zhou D, Feng F, Huang Y, Zhu H, Chen L, Wu Z, Jiang X, Li X, Jia Q, Chang Q, Pan H, Peng H, Zheng W, Huang H, Chen Z, Yang C, Chen M, Du B, Zhang S. The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria. Ann Hematol 2022. [PMID: 35965286 DOI: 10.1007/s00277-022-04933-5] [Reference Citation Analysis]
6 Notaro R, Luzzatto L. Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. N Engl J Med 2022;387:160-6. [PMID: 35830642 DOI: 10.1056/NEJMra2201664] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fattizzo B, Cavallaro F, Oliva EN, Barcellini W. Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective. J Blood Med 2022;13:327-35. [PMID: 35747742 DOI: 10.2147/JBM.S339660] [Reference Citation Analysis]
8 Risitano AM, Peffault de Latour R, Marano L, Frieri C. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls. Semin Immunol 2022;:101618. [PMID: 35764467 DOI: 10.1016/j.smim.2022.101618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kojima T, Inoue D, Wajima T, Uchida T, Yamada M, Ohsawa I, Oda T. Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis. Renal Failure 2022;44:714-23. [DOI: 10.1080/0886022x.2022.2068445] [Reference Citation Analysis]
10 Qi R, Qin W. Role of Complement System in Kidney Transplantation: Stepping From Animal Models to Clinical Application. Front Immunol 2022;13:811696. [PMID: 35281019 DOI: 10.3389/fimmu.2022.811696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Fakhouri F, Schwotzer N, Golshayan D, Frémeaux-bacchi V. The rational use of complement inhibitors in kidney diseases. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.02.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Frieri C, Peffault de Latour R, Sicre De Fontbrune F. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Emerg Drugs 2022. [PMID: 35078384 DOI: 10.1080/14728214.2022.2031973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 de Latour RP, Hosokawa K, Risitano AM. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress. Seminars in Hematology 2022. [DOI: 10.1053/j.seminhematol.2022.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gurnari C, Nautiyal I, Pagliuca S. Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Ther Clin Risk Manag 2021;17:1343-51. [PMID: 34934322 DOI: 10.2147/TCRM.S273360] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Luzzatto L. Control of hemolysis in patients with PNH. Blood 2021;138:1908-10. [PMID: 34792576 DOI: 10.1182/blood.2021013169] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
16 Ispasanie E, Muri L, Schubart A, Thorburn C, Zamurovic N, Holbro T, Kammüller M, Pluschke G. Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Front Immunol 2021;12:747594. [PMID: 34691058 DOI: 10.3389/fimmu.2021.747594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]